{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:02:22Z","timestamp":1791846142762,"version":"4.3.4"},"reference-count":78,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lipella Pharmaceuticals, Inc.","award":["DK108397"],"award-info":[{"award-number":["DK108397"]}]},{"name":"Lipella Pharmaceuticals, Inc.","award":["CA263243"],"award-info":[{"award-number":["CA263243"]}]},{"name":"NIDDK","award":["DK108397"],"award-info":[{"award-number":["DK108397"]}]},{"name":"NIDDK","award":["CA263243"],"award-info":[{"award-number":["CA263243"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bladder cancer (BC) presents a significant global health burden, characterized by high recurrence rates post-initial treatment. Gender differences in BC prevalence and response to therapy emphasize the importance of personalized treatment strategies. While Bacillus Calmette\u2013Gu\u00e9rin (BCG) remains a cornerstone of BC therapy, resistance poses a challenge, necessitating alternative strategies. Immune checkpoint inhibitors (ICIs) have shown promise, yet systemic toxicity raises concern. Intravesical administration of ICIs offers a potential solution, with recent studies demonstrating the feasibility and efficacy of intravesical pembrolizumab. Although systemic toxicity remains a concern, its localized administration may mitigate adverse events. Additionally, liposomal delivery of ICIs exhibits promises in enhancing drug penetration and reducing toxicity. Novel imaging modalities compatible with Vesical Imaging-Reporting and Data System (VI-RADS) and capable of predicting high-grade bladder cancer can aid the pre-operative shared decision making of patient and surgeon. Future research should focus on refining treatment approaches, optimizing dosing regimens, and leveraging advanced imaging techniques to improve patient outcomes. In conclusion, intravesical immunotherapy presents a promising avenue for BC treatment, offering enhanced therapeutic effectiveness while minimizing systemic toxicity. Continued research efforts are essential to validate these findings and optimize intravesical immunotherapy\u2019s role in BC management, ultimately improving patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms25094945","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T08:59:39Z","timestamp":1714553979000},"page":"4945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-4545","authenticated-orcid":false,"given":"Pradeep","family":"Tyagi","sequence":"first","affiliation":[{"name":"Departments of Urology, University of Pittsburgh, Pittsburgh, PA 15260, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hafron","sequence":"additional","affiliation":[{"name":"Michigan Institute of Urology, Troy, MI 48084, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Lipella Pharmaceuticals, Inc., Pittsburgh, PA 15208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-8972","authenticated-orcid":false,"given":"Michael","family":"Chancellor","sequence":"additional","affiliation":[{"name":"Lipella Pharmaceuticals, Inc., Pittsburgh, PA 15208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clgc.2023.12.007","article-title":"Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events","volume":"22","author":"Nizam","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.3390\/curroncol30050350","article-title":"Intravesical Contrast-Enhanced MRI: A Potential Tool for Bladder Cancer Surveillance and Staging","volume":"30","author":"Tyagi","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ahrenfeldt, J., Christensen, D.S., Ostergaard, A.B., Kisistok, J., Sokac, M., and Birkbak, N.J. (2023). The ratio of adaptive to innate immune cells differs between genders and associates with improved prognosis and response to immunotherapy. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0281375"},{"key":"ref_4","first-page":"dlad156","article-title":"Epidemiology and microbiology of recurrent UTI in women in the community in Oxfordshire, UK","volume":"6","author":"Fanshawe","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102048","DOI":"10.1016\/j.clgc.2024.01.020","article-title":"Recurrent Bacteriuria as a Prognosis Marker in the Adjuvant Treatment of Non-Muscle Invasive Bladder Cancer","volume":"22","author":"Szczesniewski","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_6","first-page":"e39","article-title":"Vaginal Estrogen Therapy Is Associated with Decreased Inflammatory Response in Postmenopausal Women With Recurrent Urinary Tract Infections","volume":"27","author":"Meister","year":"2021","journal-title":"Urogynecology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/cam4.452","article-title":"Poor survival of females with bladder cancer is limited to those aged 70 years or over: A population-wide linkage study, New South Wales, Australia","volume":"4","author":"Patel","year":"2015","journal-title":"Cancer Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102059","DOI":"10.1016\/j.clgc.2024.02.010","article-title":"Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guerin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guerin Treatment","volume":"22","author":"Montgomery","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"486.e1","DOI":"10.1016\/j.urolonc.2023.08.012","article-title":"The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta\/T1 urothelial carcinoma before and after BCG treatment","volume":"41","author":"Civriz","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Uemura, K., Ito, H., Jikuya, R., Kondo, T., Tatenuma, T., Kawahara, T., Ito, Y., Komeya, M., Muraoka, K., and Hasumi, H. (2024). Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. Int. J. Urol.","DOI":"10.1111\/iju.15437"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clgc.2023.12.001","article-title":"First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies","volume":"22","author":"Villacampa","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3390\/curroncol29020080","article-title":"Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study","volume":"29","author":"Dang","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s10147-024-02482-7","article-title":"Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab","volume":"29","author":"Hashimoto","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/2767-9764.CRC-23-0436","article-title":"Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma","volume":"4","author":"Bitting","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.eururo.2022.10.025","article-title":"Re: Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy; et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin. Eur. Urol. 2022; 82: 602\u2013610","volume":"83","author":"Steinberg","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2147\/OTT.S389138","article-title":"The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status","volume":"15","author":"Furubayashi","year":"2022","journal-title":"Onco Targets Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/j.clgc.2022.04.002","article-title":"Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab","volume":"20","author":"Goulvestre","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"837854","DOI":"10.3389\/fpubh.2022.837854","article-title":"Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma","volume":"10","author":"Xie","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Curkovic, N.B., Bai, K., Ye, F., and Johnson, D.B. (2024). Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis. Cancers, 16.","DOI":"10.3390\/cancers16020340"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hadfield, M.J., Benjamin, D.J., Krell, J., Warner, J., and Lythgoe, M.P. (2024). The evolving posology and administration of immune checkpoint inhibitors: Subcutaneous formulations. Trends Cancer.","DOI":"10.1016\/j.trecan.2024.03.006"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e008571","DOI":"10.1136\/jitc-2023-008571","article-title":"A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer","volume":"12","author":"Meghani","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35297","DOI":"10.1038\/srep35297","article-title":"High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1","volume":"6","author":"Horita","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1023\/A:1015954316139","article-title":"Size characterization of Mycobacterium bovis BCG (Bacillus Calmette Guerin) vaccine, Tice substrain","volume":"5","author":"Zhang","year":"1988","journal-title":"Pharm. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1464-410X.1983.tb03354.x","article-title":"Permeability and ultrastructure of human bladder epithelium","volume":"55","author":"Eldrup","year":"1983","journal-title":"Br. J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/luts.12319","article-title":"Sodium plays an important role in the absorption of intravesical fluid","volume":"13","author":"Morizawa","year":"2021","journal-title":"Low. Urin. Tract Symptoms"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1159\/000020335","article-title":"Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancer","volume":"38","author":"Bue","year":"2000","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1464-410X.1989.tb05159.x","article-title":"Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times","volume":"63","author":"Giesbers","year":"1989","journal-title":"Br. J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000281301","article-title":"Mitomycin C resorption following repeated intravesical instillations using different instillation times","volume":"43","author":"Rikken","year":"1988","journal-title":"Urol. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40266-023-01009-5","article-title":"Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options","volume":"40","author":"Ganguly","year":"2023","journal-title":"Drugs Aging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101041","DOI":"10.1016\/j.cont.2023.101041","article-title":"Unraveling the Complexity of bladder-centric chronic pain by intravesical contrast enhanced MRI","volume":"7","author":"Tyagi","year":"2023","journal-title":"Continence"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.juro.2009.06.039","article-title":"Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy","volume":"182","author":"Sonn","year":"2009","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100856","DOI":"10.1016\/j.cont.2023.100856","article-title":"Probing The Interplay of Perfusion and Permeability in Bladder Inflammation","volume":"7","author":"Tyagi","year":"2023","journal-title":"Continence"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"F1245","DOI":"10.1152\/ajprenal.00352.2010","article-title":"Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment","volume":"299","author":"Saban","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00997244","article-title":"Immunolocalization of transitional cell carcinoma of the bladder with intravesically administered technetium-99m labelled HMFG1 monoclonal antibody","volume":"22","author":"Malamitsi","year":"1995","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/028418699431474","article-title":"Intravesical administration of radiolabelled tumour-associated monoclonal antibody in bladder cancer","volume":"38","author":"Syrigos","year":"1999","journal-title":"Acta Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1097\/01.JU.0001008772.30001.48.07","article-title":"A Virtual Method For Measuring Bladder Blood Flow Relative to Femoral Artery","volume":"211","author":"Tyagi","year":"2024","journal-title":"J. Urol."},{"key":"ref_43","first-page":"3314","article-title":"Penetration of mitomycin C in human bladder","volume":"53","author":"Wientjes","year":"1993","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/imammb\/dqy004","article-title":"Analyzing the effects of instillation volume on intravesical delivery using biphasic solute transport in a deformable geometry","volume":"36","author":"Smith","year":"2019","journal-title":"Math Med. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19440","DOI":"10.1038\/s41598-021-98504-9","article-title":"Functional and histologic imaging of urinary bladder wall after exposure to psychological stress and protamine sulfate","volume":"11","author":"Saito","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_46","first-page":"139","article-title":"Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine","volume":"4","author":"Gao","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.urology.2013.03.036","article-title":"Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer","volume":"82","author":"Maffezzini","year":"2013","journal-title":"Urology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.2910510305","article-title":"Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times","volume":"51","author":"Sleeboom","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11255-023-03783-y","article-title":"Intravesical liposomal tacrolimus for hemorrhagic cystitis: A phase 2a multicenter dose-escalation study","volume":"56","author":"Hafron","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0022-5347(17)61228-X","article-title":"Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors","volume":"106","author":"Lunglmayr","year":"1971","journal-title":"J. Urol."},{"key":"ref_51","first-page":"1510","article-title":"E-cadherin and FGFR3 are risk factors determining prognosis of patients with bladder urothelial carcinoma","volume":"15","author":"Jing","year":"2023","journal-title":"Am. J. Transl. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0022-5347(17)62237-7","article-title":"Determination of absorption of irrigating fluid during transurethral resection of the prostate by means of radioisotopes","volume":"102","author":"Oester","year":"1969","journal-title":"J. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF00256122","article-title":"Various methods of determining irrigating fluid absorption during transurethal resection of the prostate. Theoretical and practical considerations","volume":"1","author":"Madsen","year":"1973","journal-title":"Urol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00345-021-03769-4","article-title":"Irrigation fluid absorption during transurethral bipolar and laser prostate surgery: A systematic review","volume":"40","author":"Ortner","year":"2021","journal-title":"World J. Urol."},{"key":"ref_55","first-page":"121","article-title":"Does large volume of distribution of lidocaine masks its systemic uptake from bladder?","volume":"11","author":"Tyagi","year":"2023","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00005392-199907000-00015","article-title":"Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer","volume":"162","author":"Chiou","year":"1999","journal-title":"J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.01.013","article-title":"The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study","volume":"62","author":"FJ","year":"2024","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/nau.24702","article-title":"Safety, tolerability, and efficacy of LiRIS 400 mg in women with interstitial cystitis\/bladder pain syndrome with or without Hunner lesions","volume":"40","author":"Evans","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Liu, H.T., Chen, S.H., Chancellor, M.B., and Kuo, H.C. (2015). Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134803"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_61","unstructured":"Tyagi, P., Ganguly, A., Hafron, J., Kaufman, J., and Chancellor, M. (2024). Intravesical Local Administration of Pembrolizumab for Treatment of Bladder Cancer\u2014A Novel Strategy to Minimize Toxicity. asco.org\/abstracts, e14687. Available online: https:\/\/meetings.asco.org\/abstracts-presentations\/235302."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Tyagi, P., Okonski, J., and Chancellor, M. (2023). Bladder Before Blood (BBB)- Principle For Safe Treatment of Hemorrhagic Cystitis (HC) By Anti-Inflammatory Drugs. Continence, 7.","DOI":"10.1016\/j.cont.2023.100824"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/iju.13317","article-title":"Intravesical liposome therapy for interstitial cystitis","volume":"24","author":"Tyagi","year":"2017","journal-title":"Int. J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0022-5347(01)64822-5","article-title":"Liposome encapsulated doxorubicin transfer to the pelvic lymph nodes by endoscopic administration into the bladder wall: A preliminary report","volume":"157","author":"Tsuruta","year":"1997","journal-title":"J. Urol."},{"key":"ref_65","first-page":"1635","article-title":"Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer","volume":"3","author":"Mazurchuk","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Rajaganapathy, B.R., Chancellor, M.B., Nirmal, J., Dang, L., and Tyagi, P. (2015). Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122766"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0022-5347(09)61520-2","article-title":"Intravesical liposomal (lP08) instillation protects bladder urothelium from chemical irritation","volume":"181","author":"Kaufman","year":"2009","journal-title":"J. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Jafari, N.V., and Rohn, J.L. (2023). An immunoresponsive three-dimensional urine-tolerant human urothelial model to study urinary tract infection. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1128132"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0090-4295(86)90372-9","article-title":"Absorption of anticancer drugs through bladder epithelium","volume":"27","author":"Mishina","year":"1986","journal-title":"Urology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"106207","DOI":"10.1016\/j.ejps.2022.106207","article-title":"Ultrasound responsive Gd-DOTA\/doxorubicin-loaded nanodroplet as a theranostic agent for magnetic resonance image-guided controlled release drug delivery of melanoma cancer","volume":"174","author":"Maghsoudinia","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/RLI.0000000000001029","article-title":"Uptake of Gadolinium-Based Contrast Agents by Blood Cells During Contrast-Enhanced MRI Examination","volume":"59","author":"Ruprecht","year":"2024","journal-title":"Invest. Radiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cmmi.1660","article-title":"Equilibrium-phase MR angiography: Comparison of unspecific extracellular and protein-binding gadolinium-based contrast media with respect to image quality","volume":"11","author":"Taupitz","year":"2016","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_73","first-page":"2591","article-title":"Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures","volume":"16","author":"Dong","year":"2024","journal-title":"Aging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0022-5347(17)51088-5","article-title":"In vivo staining test with methylene blue for bladder cancer","volume":"130","author":"Fukui","year":"1983","journal-title":"J. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1097\/01.JU.0001008584.88541.ff.11","article-title":"Anti-inflammatory effect of Betulinic Acid Is Dependent on Metabolic Reprogramming of Immune Cells","volume":"211","author":"Ganguly","year":"2024","journal-title":"J. Urol."},{"key":"ref_76","first-page":"S190","article-title":"Does betulinic acid, a natural anti-cancer agent, target metabolic programming in bladder cancer?","volume":"17","author":"Ganguly","year":"2023","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1016\/j.crad.2024.01.031","article-title":"Vesical Imaging-Reporting and Data System (VI-RADS) as a grouping imaging biomarker combined with a decision-tree mode to preoperatively predict the pathological grade of bladder cancer","volume":"79","author":"Cao","year":"2024","journal-title":"Clin. Radiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11255-019-02183-5","article-title":"Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics","volume":"51","author":"Slusarczyk","year":"2019","journal-title":"Int. Urol. Nephrol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:03Z","timestamp":1760107083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":78,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094945"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094945","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}